![Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study - The Lancet Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/605f4cbf-8bf2-40f2-8784-cb5399aece5a/gr1.gif)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study - The Lancet
![The connection between Nike, Marathons, and Ancient Greece | by Syed Adil | Five Guys Facts | Medium The connection between Nike, Marathons, and Ancient Greece | by Syed Adil | Five Guys Facts | Medium](https://miro.medium.com/max/645/1*GxxNPcNxSR_Iz7RQouX9xw.png)
The connection between Nike, Marathons, and Ancient Greece | by Syed Adil | Five Guys Facts | Medium
![Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study - The Lancet Oncology Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/654a8bf0-f679-4d35-8047-fc3e297944ec/gr1.jpg)